2023
DOI: 10.1080/13543776.2023.2190884
|View full text |Cite
|
Sign up to set email alerts
|

Malaria vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 63 publications
0
1
0
Order By: Relevance
“…Previous in silico and in vitro studies have shown that both ligands or peptides binding at the spike ACE2–RBD and interacting with Tyr505, Arg403, Lys417, His42, Glu37, Asn33 and Arg393 can potentially block viral cell entry. 24,31–33…”
Section: Resultsmentioning
confidence: 99%
“…Previous in silico and in vitro studies have shown that both ligands or peptides binding at the spike ACE2–RBD and interacting with Tyr505, Arg403, Lys417, His42, Glu37, Asn33 and Arg393 can potentially block viral cell entry. 24,31–33…”
Section: Resultsmentioning
confidence: 99%
“…In a randomised, phase 3 trial among children aged 5–36 months followed for 24 months, R21/Matrix-M™ prevented 75% of malaria episodes, and there was a 77% reduction in multiple malaria episodes in the vaccinated group compared to the control group in children from sites with seasonal malaria transmission [ 6 ]. Unless pre-erythrocytic stage malaria vaccines confer sterile immunity, developing effective blood-stage malaria vaccines and identifying blood-stage antigen vaccine candidates to complement pre-erythrocytic stage malaria vaccines in multi-antigen/multi-stage malaria vaccines [ 7 ] is crucial to eliminating the burden of malaria.…”
Section: Introductionmentioning
confidence: 99%